Bio-Techne Corp. (TECH) is a publicly traded Healthcare sector company. As of May 20, 2026, TECH trades at $46.69 with a market cap of $6.96B and a P/E ratio of 64.94. TECH moved +2.74% today. Year to date, TECH is -25.91%; over the trailing twelve months it is -5.71%. Its 52-week range spans $43.20 to $80.80. Analyst consensus is buy with an average price target of $59.25. Rallies surfaces TECH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bio-Techne sinks as fiscal Q3 revenue misses on weaker academic demand: Bio-Techne shares fell after fiscal Q3 2026 results missed Wall Street revenue expectations, with sales down 2% year over year to $311.4 million. Management pointed to demand pressure tied to weaker U.S. academic funding plus a tough comparison from prior-year GMP fast‑track orders and shipment timing.
| Metric | Value |
|---|---|
| Price | $46.69 |
| Market Cap | $6.96B |
| P/E Ratio | 64.94 |
| EPS | $0.71 |
| Dividend Yield | 0.08% |
| 52-Week High | $80.80 |
| 52-Week Low | $43.20 |
| Volume | 2.26M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.21B |
| Net Income | $109.56M |
| Gross Margin | 64.96% |
10 analysts cover TECH: 0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $59.25.